Integra LifeSciences
Corporate brand
UnclaimedMedical technology company supplying regenerative tissue products, neurosurgical technologies, wound-care systems, and surgical instruments.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Integra LifeSciences is a United States-based medical technology company headquartered in Princeton, New Jersey. It develops, manufactures, and markets products used in skin regeneration, neurosurgery, reconstructive surgery, general surgery, and wound management. The company is particularly associated with regenerative tissue technologies, including its Integra Dermal Regeneration Template, as well as neurosurgical monitoring, cerebrospinal-fluid-management, surgical-navigation, and operative-instrumentation products. The company was established in 1989 by Richard Caruso after he licensed artificial-skin technology developed through research associated with Harvard Medical School and the Massachusetts Institute of Technology and acquired Colla-tec, a Marion Laboratories subsidiary. The underlying artificial-skin research had been advanced by surgeon John F. Burke and MIT professor Ioannis V. Yannas beginning in the late 1960s. Their work produced a reproducible skin-substitute technology intended to help patients with extensive burns and other complex wounds. Integra's product uses a temporary silicone outer layer and a collagen-based regenerative layer that provides a scaffold for the growth of new tissue. This technology helped define the company's original regenerative-medicine identity. Integra received United States Food and Drug Administration approval for its artificial skin in 1996. It later expanded the approved and marketed uses of the technology, including reconstructive treatment of burn scars and, after a 2016 premarket approval, certain diabetic foot ulcers. The company also broadened its portfolio through internal development and acquisitions. Its neurosurgical business includes products such as DuraGen absorbable dural grafts, Licox brain-tissue oxygen and temperature monitoring technology, CUSA ultrasonic surgical aspiration systems, Mayfield cranial stabilization equipment, and products associated with Codman Neurosurgery. Its regenerative-medicine portfolio has included SurgiMend, PriMatrix, and other tissue-repair scaffolds, while its wound-care range has included systems for diabetic-foot-ulcer treatment and pressure management. A major phase of expansion occurred through acquisitions. Integra bought surgical instrumentation lines from Medtronic, acquired Covidien's Confluent Surgical sealants and shields business, purchased TEI Biosciences and TEI Medical, and acquired Derma Sciences. In 2017 it purchased Johnson & Johnson's Codman Neurosurgery business, significantly increasing its presence in neurosurgical devices. In 2021 it acquired ACell, a regenerative-medicine company, and in 2024 it completed the acquisition of Acclarent, adding a business focused on ear, nose, and throat surgical technologies. Integra serves hospitals, surgical centers, neurosurgeons, general surgeons, reconstructive surgeons, burn-care specialists, wound-care clinicians, and other healthcare professionals. Its positioning combines specialized clinical technologies with procedure-oriented products used in acute-care and reconstructive settings. The company has been described in industry rankings as one of the larger global medical technology businesses and was included in Fortune's 2018 list of fastest-growing companies. Integra remains an active publicly traded medical-device company under the NASDAQ ticker IART.
History
Integra LifeSciences traces its technological origins to artificial-skin research begun in 1969 by John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a professor of fiber and polymer science at MIT. Their work sought to create a reproducible substitute for human skin that could assist patients with severe burns, for whom conventional grafting options were limited. The resulting technology combined a protective silicone layer with a biologically derived regenerative layer. The silicone helped limit fluid loss and exposure, while the lower layer acted as a framework for the formation of new tissue. Richard Caruso founded Integra LifeSciences in 1989 after licensing the artificial-skin technology and acquiring Colla-tec, a subsidiary of Marion Laboratories. The new company built its initial identity around regenerative medicine and the clinical potential of artificial skin. In 1996, the United States Food and Drug Administration approved Integra's artificial-skin product for severe burns. The product became notable as an early commercially reproducible skin-tissue technology and was subsequently used in burn care, reconstructive procedures, plastic surgery, and treatment of selected complex wounds. Integra then developed a broader surgical and neurosurgical platform. In 1999, the FDA approved DuraGen, an absorbable implant used in neurosurgical and spinal procedures. The company also expanded through the acquisition of NMT and related technology, including Licox, a system for monitoring brain-tissue oxygen and temperature in critically ill patients, including people with traumatic brain injuries. In 2002, the FDA approved use of the Integra Dermal Regeneration Template in reconstructive surgery for burn scars. A later regulatory milestone came in 2016, when the product received premarket approval for treatment of diabetic foot ulcers. Acquisitions became a central part of Integra's portfolio strategy. The company acquired Covidien's Confluent Surgical line of sealants and shields in 2014 and purchased instrumentation lines from Medtronic later that year. In 2015, it acquired TEI Biosciences and TEI Medical, bringing the SurgiMend and PriMatrix product families into the organization. In 2017, Integra acquired Derma Sciences, adding wound-care technologies such as the TCC-EZ Total Contact Cast. That same year, it acquired Johnson & Johnson's Codman Neurosurgery business. Codman added established neurosurgical products, including systems for hydrocephalus management such as the Codman Hakim valve, and strengthened Integra's role in cranial and neurosurgical care. The company continued its regenerative-medicine expansion with the acquisition of ACell in 2021. ACell added biologic tissue-repair capabilities and broadened Integra's presence in wound management and reconstruction. In 2024, Integra completed the acquisition of Acclarent, extending its surgical technology portfolio into ear, nose, and throat procedures. Integra became publicly traded under the NASDAQ ticker IART and developed into a global medical-device manufacturer serving hospitals, surgical centers, and specialist clinicians. Its business spans regenerative tissue matrices, neurosurgical implants and monitoring, wound-care systems, surgical instruments, ultrasonic tissue-removal equipment, and patient-positioning products. Public descriptions of the company have emphasized its role in skin regeneration, neurosurgery, reconstructive surgery, and general surgery. Integra was included in Fortune's 2018 fastest-growing-companies list and was ranked 59th in Medical Design and Outsourcing's 2023 list of large medical technology companies.
- 2024
Acclarent acquisition is completed
[1]Integra completes its acquisition of Acclarent and adds ear, nose, and throat surgical technologies.
- 2021
ACell is acquired
[1]The $400 million acquisition adds regenerative-medicine products and capabilities.
- 2017
Derma Sciences is acquired
[1]Integra adds wound-care products, including the TCC-EZ Total Contact Cast.
- 2017
Codman Neurosurgery is acquired
[1]Integra acquires Johnson & Johnson's Codman Neurosurgery business and expands its neurosurgical platform.
- 2016
Dermal Regeneration Template gains diabetic-foot-ulcer approval
[1]The product receives FDA premarket approval for treatment of diabetic foot ulcers.
- 2015
TEI Biosciences and TEI Medical are acquired
[1]The acquisition adds SurgiMend and PriMatrix regenerative-tissue products.
- 2014
Surgical-product portfolio expands
[1]Integra acquires Covidien's Confluent Surgical line and instrumentation lines from Medtronic.
- 2002
Dermal Regeneration Template gains reconstructive indication
[1]The FDA approves the Integra Dermal Regeneration Template for reconstructive treatment of burn scars.
- 1999
DuraGen receives FDA approval
[1]DuraGen is approved for use as an absorbable implant in neurosurgical and spinal procedures.
- 1996
Artificial skin receives FDA approval
[1]Integra's artificial-skin product receives United States approval for severe-burn treatment.
Products and positioning
Specialized medical technology provider focused on regenerative medicine, neurosurgery, wound repair, and surgical procedure support.
Regenerative medicine and wound repair · 1996
Integra Dermal Regeneration Template
A bilayer skin-regeneration product originally developed for severe burns and later used in reconstructive surgery, burn-scar treatment, plastic surgery, and selected complex wounds. Its silicone layer provides temporary coverage, while the underlying biological matrix supports the formation of new dermal tissue. The product also received FDA premarket approval for certain diabetic foot ulcers.
Neurosurgical implant · 1999
DuraGen
An absorbable implant used in neurosurgical and spinal procedures. DuraGen is designed to support dural repair and is part of Integra's long-standing portfolio of products for cranial and spinal surgery.
Neurocritical-care monitoring
Licox
A brain-tissue oxygen and temperature monitoring technology used in critical-care settings. It is intended to support the management of patients with serious neurological injuries, including traumatic brain injuries, by providing clinicians with physiological information from brain tissue.
Neurosurgical and general-surgical equipment
CUSA Clarity
An ultrasonic surgical aspiration platform used to fragment and remove selected tissue during operative procedures. It represents Integra's focus on specialized surgical equipment for neurosurgery and other procedures requiring controlled tissue removal.
Surgical positioning equipment
Mayfield Headrest System
A cranial stabilization and positioning system used during neurosurgical procedures. The product family supports secure patient positioning and operative access in cranial surgery.
Regenerative tissue matrix · 2015
SurgiMend
A regenerative-tissue matrix added to Integra's portfolio through the acquisition of TEI Biosciences and TEI Medical. It is used in soft-tissue repair and reconstructive applications where a biologic scaffold is required.
Dermal repair scaffold · 2015
PriMatrix
A dermal repair scaffold used in wound management and reconstructive procedures, including applications involving diabetic foot ulcers and burns. The product became part of Integra's regenerative-medicine range through the TEI acquisition.
Wound care · 2017
TCC-EZ Total Contact Cast
A total-contact-casting system used in the management of diabetic foot ulcers. Its design is intended to reduce pressure on the affected foot and make application faster than conventional total-contact casting techniques.
Hydrocephalus management
Codman Hakim valve
A cerebrospinal-fluid shunt valve associated with the Codman Neurosurgery portfolio. It was developed as a device for managing hydrocephalus and became part of Integra's neurosurgical business through the acquisition of Codman Neurosurgery.
Brand decisions
2024
Complete Acclarent acquisitionM&ABackground
Integra pursued expansion into additional specialty surgical markets.
Action taken
The company completed its acquisition of Acclarent, adding ear, nose, and throat surgical technologies.
Aftermath
The transaction extended Integra's specialty-procedure portfolio into otolaryngology.
2021
Acquire ACellM&ABackground
Integra continued to expand its regenerative-medicine and tissue-repair capabilities.
Action taken
Integra acquired regenerative-medicine company ACell for $400 million.
Aftermath
ACell's regenerative-medicine technologies broadened Integra's wound-care and reconstruction portfolio.
Acquisition value. $400 million (2021)
2017
Acquire Derma SciencesM&ABackground
Integra aimed to enlarge its wound-care business and add products for diabetic foot-ulcer management.
Action taken
Integra acquired Derma Sciences for $204 million.
Aftermath
The transaction added products including the TCC-EZ Total Contact Cast.
Acquisition value. $204 million (2017)
2017
Acquire Codman Neurosurgery from Johnson & JohnsonM&ABackground
Integra sought to establish a larger and more comprehensive position in neurosurgical devices.
Action taken
The company acquired Johnson & Johnson's Codman Neurosurgery business for $1.045 billion.
Aftermath
The acquisition added Codman's neurosurgical products, including the Codman Hakim valve, and materially expanded Integra's cranial and neurosurgical offering.
Acquisition value. $1.045 billion (2017)
2015
Acquire TEI Biosciences and TEI MedicalM&ABackground
Integra pursued additional regenerative-medicine products and tissue-repair technologies.
Action taken
The company acquired TEI Biosciences and TEI Medical, adding the SurgiMend and PriMatrix product lines.
Aftermath
The acquisition strengthened Integra's presence in biologic scaffolds and reconstructive tissue repair.
2014
Acquire Confluent Surgical products and Medtronic instrumentation linesM&ABackground
Integra sought to broaden its surgical-product portfolio beyond its established regenerative-medicine and neurosurgical businesses.
Action taken
The company acquired Covidien's Confluent Surgical line of sealants and shields and separately acquired instrumentation lines from Medtronic.
Aftermath
The transactions expanded Integra's access to surgical sealants, barriers, and instruments.
Recent events
Reported
Integra LifeSciences reports 2021 financial results[3]
Integra LifeSciences reported financial results for the fourth quarter and full year ended December 31, 2021.
Reported
Integra LifeSciences provides 2022 financial guidance[3]
Integra LifeSciences provided financial guidance for 2022.
Reported
Smith & Nephew completes acquisition of extremity orthopedics business[4]
Smith & Nephew completed its $240 million acquisition of Integra LifeSciences' extremity orthopedics business unit.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/integra-lifesciences · Editorial policy · How profiles are compiled